{"id":243188,"date":"2026-09-11T10:38:41","date_gmt":"2026-09-11T05:08:41","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=243188"},"modified":"2026-09-11T10:38:41","modified_gmt":"2026-09-11T05:08:41","slug":"healthcare-tech-stock-rises-29-percent-in-6-months","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/","title":{"rendered":"This Healthcare Tech Stock Rises 29% in 6 Months: What Is Behind the Move?"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>CMP approx Rs 1,757 (11 Sep 2026). 6-month return 29.48%. 52W range Rs 1,262 to Rs 1,933. Market cap approx Rs 30,749 Cr. FY26 PAT Rs 722 Cr, up 48%.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Inventurus Knowledge Solutions (IKS Health), which runs clinical and billing operations for US health systems, is the healthcare tech stock behind a 6-month return of approximately 29%. The share climbed on a 48% jump in FY26 profit and the USD 557 million TruBridge acquisition, which is expected to add to earnings from FY27. It still trades about 6% below its December 2024 listing price, and the PE near 40 is well above the industry average.<\/p>\n<\/div>\n<p>This healthcare tech stock has added approximately 29% in six months, turning Rs 1 lakh into roughly Rs 1.29 lakh since March 2026. A company that runs clinical and billing operations for US health systems posted a 6-month return of 29.48% as of 10 September 2026, ranking 51st in a screen of 101 large-cap and mid-cap NSE shares.<\/p>\n<p>The company is <strong><a href='https:\/\/univest.in\/stocks\/iks\/inventurus-knowledge-so-l-share-price-today'>Inventurus Knowledge Solutions Ltd<\/a> (NSE: IKS)<\/strong>, better known by its brand IKS Health. The Inventurus Knowledge Solutions share price closed at Rs 1,783.70 on 10 September 2026, giving it a market value of approximately Rs 30,749 crore. This healthcare tech stock rose on a strong FY26 earnings run and a large US acquisition in April 2026, though its longer record is less flattering.<\/p>\n<p style=\"margin-top:24px;\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#How_Much_Has_This_Healthcare_Tech_Stock_Gained_in_6_Months\" title=\"How Much Has This Healthcare Tech Stock Gained in 6 Months?\">How Much Has This Healthcare Tech Stock Gained in 6 Months?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Why_Did_This_Healthcare_Tech_Stock_Rise_29_in_6_Months\" title=\"Why Did This Healthcare Tech Stock Rise 29% in 6 Months?\">Why Did This Healthcare Tech Stock Rise 29% in 6 Months?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#1_FY26_Profit_Jumped_48_on_Margin_Expansion\" title=\"1. FY26 Profit Jumped 48% on Margin Expansion\">1. FY26 Profit Jumped 48% on Margin Expansion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#2_The_TruBridge_Deal_Lifted_the_Growth_Outlook\" title=\"2. The TruBridge Deal Lifted the Growth Outlook\">2. The TruBridge Deal Lifted the Growth Outlook<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#3_AI_Products_and_Large_Health_System_Wins\" title=\"3. AI Products and Large Health System Wins\">3. AI Products and Large Health System Wins<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Inventurus_Knowledge_Solutions_Share_Price_and_Quarterly_Financials\" title=\"Inventurus Knowledge Solutions Share Price and Quarterly Financials\">Inventurus Knowledge Solutions Share Price and Quarterly Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Is_This_Healthcare_Tech_Stock_Expensive_Now\" title=\"Is This Healthcare Tech Stock Expensive Now?\">Is This Healthcare Tech Stock Expensive Now?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#How_Institutions_Have_Backed_This_Healthcare_Tech_Stock\" title=\"How Institutions Have Backed This Healthcare Tech Stock\">How Institutions Have Backed This Healthcare Tech Stock<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Key_Risks_for_This_Healthcare_Tech_Stock\" title=\"Key Risks for This Healthcare Tech Stock\">Key Risks for This Healthcare Tech Stock<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Higher_Debt_After_TruBridge\" title=\"Higher Debt After TruBridge\">Higher Debt After TruBridge<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#TruBridge_Revenue_Reset\" title=\"TruBridge Revenue Reset\">TruBridge Revenue Reset<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Currency_and_US_Policy_Exposure\" title=\"Currency and US Policy Exposure\">Currency and US Policy Exposure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#AI_Disruption_and_Competition\" title=\"AI Disruption and Competition\">AI Disruption and Competition<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Rich_Valuation\" title=\"Rich Valuation\">Rich Valuation<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Inventurus_Knowledge_Solutions_Share_Analyst_View\" title=\"Inventurus Knowledge Solutions Share: Analyst View\">Inventurus Knowledge Solutions Share: Analyst View<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Inventurus_Knowledge_Solutions_Share_Price_Target\" title=\"Inventurus Knowledge Solutions Share Price Target\">Inventurus Knowledge Solutions Share Price Target<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Which_healthcare_tech_stock_rose_29_in_6_months\" title=\"Which healthcare tech stock rose 29% in 6 months?\">Which healthcare tech stock rose 29% in 6 months?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Why_did_the_Inventurus_Knowledge_Solutions_share_price_rise\" title=\"Why did the Inventurus Knowledge Solutions share price rise?\">Why did the Inventurus Knowledge Solutions share price rise?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#What_were_Inventurus_Knowledge_Solutions_Q1_FY27_results\" title=\"What were Inventurus Knowledge Solutions Q1 FY27 results?\">What were Inventurus Knowledge Solutions Q1 FY27 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Is_Inventurus_Knowledge_Solutions_trading_above_its_IPO_price\" title=\"Is Inventurus Knowledge Solutions trading above its IPO price?\">Is Inventurus Knowledge Solutions trading above its IPO price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#What_is_the_52-week_high_and_low_of_Inventurus_Knowledge_Solutions\" title=\"What is the 52-week high and low of Inventurus Knowledge Solutions?\">What is the 52-week high and low of Inventurus Knowledge Solutions?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#What_is_the_Inventurus_Knowledge_Solutions_share_price_target\" title=\"What is the Inventurus Knowledge Solutions share price target?\">What is the Inventurus Knowledge Solutions share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#Is_this_healthcare_tech_stock_overvalued\" title=\"Is this healthcare tech stock overvalued?\">Is this healthcare tech stock overvalued?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/healthcare-tech-stock-rises-29-percent-in-6-months\/#What_are_the_main_risks_for_Inventurus_Knowledge_Solutions\" title=\"What are the main risks for Inventurus Knowledge Solutions?\">What are the main risks for Inventurus Knowledge Solutions?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"How_Much_Has_This_Healthcare_Tech_Stock_Gained_in_6_Months\"><\/span><strong>How Much Has This Healthcare Tech Stock Gained in 6 Months?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This healthcare tech stock has gained approximately 29.48% in six months, from around Rs 1,378 in mid-March 2026 to Rs 1,783.70 on 10 September 2026. That places this healthcare tech stock at rank 51 in our 101-stock screen, a solid move but not a runaway rally.<\/p>\n<p>The other time frames give a more mixed picture of this healthcare tech stock. Here is how it has performed across periods in the screen:<\/p>\n<table>\n<thead>\n<tr>\n<th>Period<\/th>\n<th>Return (%)<\/th>\n<th>Rank (out of 101)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1 Month<\/td>\n<td>1.70%<\/td>\n<td>78<\/td>\n<\/tr>\n<tr>\n<td>6 Months<\/td>\n<td>29.48%<\/td>\n<td>51<\/td>\n<\/tr>\n<tr>\n<td>1 Year<\/td>\n<td>22.11%<\/td>\n<td>59<\/td>\n<\/tr>\n<tr>\n<td>Since Listing (Dec 2024)<\/td>\n<td>-6.17%<\/td>\n<td>Not ranked<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The since-listing figure is measured from the NSE listing price of Rs 1,900 on 19 December 2024, when the share opened at a 43% premium to its IPO price of Rs 1,329. Investors who bought on listing day are still slightly under water, while IPO allottees are sitting on a gain of roughly 34%.<\/p>\n<p>There was no split or bonus in the window, so the 29% move in this healthcare tech stock is real price appreciation. The face value remains Rs 1 per share.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Why_Did_This_Healthcare_Tech_Stock_Rise_29_in_6_Months\"><\/span><strong>Why Did This Healthcare Tech Stock Rise 29% in 6 Months?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This healthcare tech stock rose 29% in six months because profits grew much faster than revenue, and because the TruBridge acquisition gave investors a clear path to a far larger business. Three triggers did most of the work.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"1_FY26_Profit_Jumped_48_on_Margin_Expansion\"><\/span><strong>1. FY26 Profit Jumped 48% on Margin Expansion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Inventurus Knowledge Solutions reported FY26 revenue of Rs 3,211 crore, up approximately 19% from Rs 2,703 crore in FY25. Net profit rose far faster, climbing approximately 48% to Rs 722 crore from Rs 486 crore.<\/p>\n<p>The gap came from margins. The operating margin improved to 34.48% in FY26 from 30.42% a year earlier, as automation reduced the cost of each process handled. For a healthcare tech stock, that margin gain signals pricing power rather than just volume.<\/p>\n<p>Q4 FY26 results, released in May 2026, kept the momentum going for this healthcare tech stock. Revenue rose around 18% in rupee terms and 13% in dollar terms, while quarterly profit reached approximately Rs 206 crore, up about 39% year on year.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"2_The_TruBridge_Deal_Lifted_the_Growth_Outlook\"><\/span><strong>2. The TruBridge Deal Lifted the Growth Outlook<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>On 23 April 2026, the US subsidiary of the company agreed to buy TruBridge, a US provider of billing and health record software, for USD 26.25 per share in cash. The enterprise value was approximately USD 557 million, funded mainly by a five-year loan of around USD 600 million from three global banks.<\/p>\n<p>TruBridge brought roughly USD 347 million of revenue and USD 69 million of adjusted EBITDA, along with more than 1,500 clients, many of them rural and community hospitals. Management said the deal would add to earnings per share in FY27 and set a target of Rs 3,000 crore of EBITDA by FY30, roughly three times the level of calendar 2025.<\/p>\n<p>The market liked the plan. This healthcare tech stock jumped as much as 9.5% intraday to Rs 1,572.80 the day after the announcement. The deal closed on 9 July 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"3_AI_Products_and_Large_Health_System_Wins\"><\/span><strong>3. AI Products and Large Health System Wins<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This healthcare tech stock has pitched an &#8220;AI plus human&#8221; model in which software handles routine coding, documentation and billing tasks while trained staff manage exceptions. During FY26 it launched an autonomous coding engine integrated with a leading US health record platform, and an agentic AI patient engagement tool called MyCareHub.<\/p>\n<p>Client additions have also supported this healthcare tech stock. Management highlighted wins with a large California health system and Advocate Health in the Q1 FY27 call. These accounts matter because this healthcare tech stock earns most of its revenue from long, multi-year contracts that grow as clients add services.<\/p>\n<p style=\"margin-top:24px;\"><strong>Check the Univest Screener for Live Fundamentals of High-Return Stocks<\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Inventurus_Knowledge_Solutions_Share_Price_and_Quarterly_Financials\"><\/span><strong>Inventurus Knowledge Solutions Share Price and Quarterly Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The quarterly numbers of this healthcare tech stock show a steady climb, with a small dip in Q1 FY27 margins due to one-time acquisition costs. The figures below are consolidated and include other income.<\/p>\n<table>\n<thead>\n<tr>\n<th>Quarter<\/th>\n<th>Revenue (Rs Cr)<\/th>\n<th>EBITDA (Rs Cr)<\/th>\n<th>Operating Margin<\/th>\n<th>Net Profit (Rs Cr)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Jun 2025 (Q1 FY26)<\/td>\n<td>743<\/td>\n<td>241<\/td>\n<td>32.54%<\/td>\n<td>152<\/td>\n<\/tr>\n<tr>\n<td>Sep 2025 (Q2 FY26)<\/td>\n<td>785<\/td>\n<td>275<\/td>\n<td>35.08%<\/td>\n<td>181<\/td>\n<\/tr>\n<tr>\n<td>Dec 2025 (Q3 FY26)<\/td>\n<td>821<\/td>\n<td>287<\/td>\n<td>34.94%<\/td>\n<td>183<\/td>\n<\/tr>\n<tr>\n<td>Mar 2026 (Q4 FY26)<\/td>\n<td>863<\/td>\n<td>305<\/td>\n<td>34.94%<\/td>\n<td>206<\/td>\n<\/tr>\n<tr>\n<td>Jun 2026 (Q1 FY27)<\/td>\n<td>899<\/td>\n<td>301<\/td>\n<td>33.05%<\/td>\n<td>194<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>In Q1 FY27, revenue grew approximately 21% year on year, EBITDA rose about 25% and net profit increased nearly 28%. Constant currency growth was a lower 12%, which means a weaker rupee added a meaningful part of the reported growth for this healthcare tech stock.<\/p>\n<p>Profit fell about 6% from the March quarter because integration costs of roughly Rs 20 crore hit Q1 margins. Q2 FY27 will be the first quarter to show the combined business properly.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Is_This_Healthcare_Tech_Stock_Expensive_Now\"><\/span><strong>Is This Healthcare Tech Stock Expensive Now?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Yes, on trailing numbers this healthcare tech stock trades at a clear premium. It carries a PE of approximately 40 against an industry PE of about 18, and a price to book ratio of about 10.9.<\/p>\n<table>\n<thead>\n<tr>\n<th>Metric<\/th>\n<th>Value<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Current Market Price (11 Sep 2026)<\/td>\n<td>Approximately Rs 1,757<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Approximately Rs 30,749 Cr<\/td>\n<\/tr>\n<tr>\n<td>PE Ratio (TTM)<\/td>\n<td>40.03<\/td>\n<\/tr>\n<tr>\n<td>Industry PE<\/td>\n<td>17.93<\/td>\n<\/tr>\n<tr>\n<td>Price to Book<\/td>\n<td>10.92<\/td>\n<\/tr>\n<tr>\n<td>Return on Equity<\/td>\n<td>25.77%<\/td>\n<\/tr>\n<tr>\n<td>Debt to Equity (pre-deal)<\/td>\n<td>0.27<\/td>\n<\/tr>\n<tr>\n<td>52-Week High \/ Low<\/td>\n<td>Rs 1,933 \/ Rs 1,262<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>The premium for this healthcare tech stock reflects high returns on equity and consistent profit growth. Management has cited a decade of profitable growth with a PAT CAGR of about 46%.<\/p>\n<p>On 11 September 2026, the Inventurus Knowledge Solutions share price opened lower and traded near Rs 1,757, down about 1.5% from the previous close of Rs 1,783.70. That is around 9% below the 52-week high of Rs 1,933 and about 39% above the 52-week low of Rs 1,262.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_Institutions_Have_Backed_This_Healthcare_Tech_Stock\"><\/span><strong>How Institutions Have Backed This Healthcare Tech Stock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Institutional ownership in this healthcare tech stock has risen steadily since listing. Foreign institutional investors lifted their stake from 5.38% in March 2025 to 8.01% in June 2026, while domestic institutions nearly doubled their holding from 4.02% to 7.50%.<\/p>\n<table>\n<thead>\n<tr>\n<th>Shareholder<\/th>\n<th>Jun 2025<\/th>\n<th>Sep 2025<\/th>\n<th>Dec 2025<\/th>\n<th>Mar 2026<\/th>\n<th>Jun 2026<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Promoters<\/td>\n<td>63.72%<\/td>\n<td>63.72%<\/td>\n<td>63.72%<\/td>\n<td>63.72%<\/td>\n<td>63.72%<\/td>\n<\/tr>\n<tr>\n<td>FIIs<\/td>\n<td>6.50%<\/td>\n<td>7.02%<\/td>\n<td>7.56%<\/td>\n<td>8.19%<\/td>\n<td>8.01%<\/td>\n<\/tr>\n<tr>\n<td>DIIs<\/td>\n<td>4.33%<\/td>\n<td>4.89%<\/td>\n<td>6.06%<\/td>\n<td>6.40%<\/td>\n<td>7.50%<\/td>\n<\/tr>\n<tr>\n<td>Public<\/td>\n<td>22.88%<\/td>\n<td>21.90%<\/td>\n<td>20.29%<\/td>\n<td>19.39%<\/td>\n<td>18.55%<\/td>\n<\/tr>\n<tr>\n<td>Others<\/td>\n<td>2.57%<\/td>\n<td>2.46%<\/td>\n<td>2.37%<\/td>\n<td>2.31%<\/td>\n<td>2.22%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Promoter holding in this healthcare tech stock has stayed unchanged at 63.72%, which signals no fresh founder selling after the IPO. Several mutual funds hold the Inventurus Knowledge Solutions share, and retail holding has fallen as institutions absorbed supply.<\/p>\n<p>FII holding slipped slightly in the June 2026 quarter, but the rise in DII holding more than offset it.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_This_Healthcare_Tech_Stock\"><\/span><strong>Key Risks for This Healthcare Tech Stock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The rally has real support, but this healthcare tech stock carries risks worth weighing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Higher_Debt_After_TruBridge\"><\/span><strong>Higher Debt After TruBridge<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This healthcare tech stock was close to debt free before the deal, with a debt to equity ratio of 0.27. The USD 600 million loan changes that. Management expects net debt to settle near Rs 300 crore by FY30, but that depends on strong cash generation over the next few years.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"TruBridge_Revenue_Reset\"><\/span><strong>TruBridge Revenue Reset<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>After closing, management said TruBridge revenue had been reset lower by around USD 40 million a year because of more conservative accounting and customer adjustments. That was not fully expected before the deal, and integration surprises of this kind can weigh on the Inventurus Knowledge Solutions share price.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Currency_and_US_Policy_Exposure\"><\/span><strong>Currency and US Policy Exposure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Almost all revenue of this healthcare tech stock comes from US clients. A stronger rupee would cut reported growth, as the gap between 21% rupee growth and 12% constant currency growth in Q1 FY27 shows. Changes in US healthcare reimbursement rules could also slow client spending.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"AI_Disruption_and_Competition\"><\/span><strong>AI Disruption and Competition<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Agentic AI tools are pushing down the fees charged for billing and coding work across the industry. If pricing falls faster than this healthcare tech stock can automate, margins could come under pressure. Rival point solution vendors are also expanding into broader platforms that compete with this healthcare tech stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Rich_Valuation\"><\/span><strong>Rich Valuation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>A PE near 40, more than twice the industry average, leaves little room for a weak quarter. Any delay in the FY30 EBITDA path could trigger a sharp correction in this healthcare tech stock.<\/p>\n<p style=\"margin-top:24px;\"><strong>Download the <a href=\"https:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"https:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the Inventurus Knowledge Solutions share price live<\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Inventurus_Knowledge_Solutions_Share_Analyst_View\"><\/span><strong>Inventurus Knowledge Solutions Share: Analyst View<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Analysts covering the company have turned more constructive since the TruBridge deal, largely because it is expected to add to earnings per share from FY27. The core investment case for this healthcare tech stock rests on three things: steady growth with existing US health systems, margin gains from automation, and cross-selling to the combined client base, which management sizes at around USD 575 million.<\/p>\n<p>The debate around this healthcare tech stock is about the price already paid. Bulls argue that a business with returns on equity above 25% and profit growth near 30% deserves a premium. Bears point to the new debt, the TruBridge revenue reset and the pressure AI puts on outsourcing fees.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Inventurus_Knowledge_Solutions_Share_Price_Target\"><\/span><strong>Inventurus Knowledge Solutions Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The consensus Inventurus Knowledge Solutions share price target from nine analysts is approximately Rs 1,965. That implies about 12% upside from the current level near Rs 1,757, and is slightly above the 52-week high of Rs 1,933.<\/p>\n<p>Beyond the consensus Inventurus Knowledge Solutions share price target, the key levels to watch are the 52-week high of Rs 1,933 on the upside and the April 2026 breakout zone near Rs 1,570 on the downside. A sustained move above the listing price of Rs 1,900 would also turn the since-listing return positive for this healthcare tech stock.<\/p>\n<p>Targets for a healthcare tech stock are revised often as results unfold, so treat them as one input among many.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This healthcare tech stock rose about 29% in six months on the back of a 48% jump in FY26 profit, margin gains from automation and a transformational TruBridge acquisition. Institutions have been steady buyers of this healthcare tech stock and promoter holding has stayed firm.<\/p>\n<p>The risks are just as clear: higher debt, a revenue reset at TruBridge, currency exposure and a valuation well above the industry. The Inventurus Knowledge Solutions share price is still below its listing price, a reminder that returns depend heavily on entry point. Q2 FY27 results, the first full quarter with TruBridge, will be the next real test for this healthcare tech stock.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Which_healthcare_tech_stock_rose_29_in_6_months\"><\/span><strong>Which healthcare tech stock rose 29% in 6 months?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Inventurus Knowledge Solutions (NSE: IKS), also known as IKS Health, is the healthcare tech stock that gained approximately 29.48% in six months as of 10 September 2026. It ranked 51st among 101 large-cap and mid-cap NSE stocks screened.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Why_did_the_Inventurus_Knowledge_Solutions_share_price_rise\"><\/span><strong>Why did the Inventurus Knowledge Solutions share price rise?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The share rose on a 48% jump in FY26 net profit to Rs 722 crore, better operating margins and the acquisition of US-based TruBridge for an enterprise value of about USD 557 million. The deal is expected to add to earnings per share from FY27.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_were_Inventurus_Knowledge_Solutions_Q1_FY27_results\"><\/span><strong>What were Inventurus Knowledge Solutions Q1 FY27 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Consolidated revenue rose approximately 21% year on year to Rs 899 crore and net profit grew about 28% to Rs 194 crore. Constant currency growth was 12%, and integration costs of around Rs 20 crore trimmed margins.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Inventurus_Knowledge_Solutions_trading_above_its_IPO_price\"><\/span><strong>Is Inventurus Knowledge Solutions trading above its IPO price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Yes, the share trades roughly 34% above its IPO price of Rs 1,329 based on the 10 September close. However, it is about 6% below its NSE listing price of Rs 1,900, so listing-day buyers are still slightly in the red.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52-week_high_and_low_of_Inventurus_Knowledge_Solutions\"><\/span><strong>What is the 52-week high and low of Inventurus Knowledge Solutions?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 52-week high is Rs 1,933 and the 52-week low is Rs 1,262 on NSE. The share traded near Rs 1,757 on 11 September 2026, down about 1.5% for the day.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Inventurus_Knowledge_Solutions_share_price_target\"><\/span><strong>What is the Inventurus Knowledge Solutions share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The consensus target from nine analysts is approximately Rs 1,965, implying about 12% upside from around Rs 1,757. Targets are estimates and can change after each quarterly result.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_healthcare_tech_stock_overvalued\"><\/span><strong>Is this healthcare tech stock overvalued?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> It trades at a PE of approximately 40 versus an industry PE of about 18, which is a clear premium for a healthcare tech stock. That premium reflects high returns on equity and strong profit growth, but it leaves little room for disappointment.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_risks_for_Inventurus_Knowledge_Solutions\"><\/span><strong>What are the main risks for Inventurus Knowledge Solutions?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks include higher debt from the TruBridge purchase, a lower-than-expected TruBridge revenue base, dependence on US clients and currency moves, and fee pressure from AI tools. A SEBI-registered advisor can help assess whether the stock suits your portfolio.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"Which healthcare tech stock rose 29% in 6 months?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Inventurus Knowledge Solutions (NSE: IKS), also known as IKS Health, is the healthcare tech stock that gained approximately 29.48% in six months as of 10 September 2026. It ranked 51st among 101 large-cap and mid-cap NSE stocks screened.\"}},{\"@type\":\"Question\",\"name\":\"Why did the Inventurus Knowledge Solutions share price rise?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The share rose on a 48% jump in FY26 net profit to Rs 722 crore, better operating margins and the acquisition of US-based TruBridge for an enterprise value of about USD 557 million. The deal is expected to add to earnings per share from FY27.\"}},{\"@type\":\"Question\",\"name\":\"What were Inventurus Knowledge Solutions Q1 FY27 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Consolidated revenue rose approximately 21% year on year to Rs 899 crore and net profit grew about 28% to Rs 194 crore. Constant currency growth was 12%, and integration costs of around Rs 20 crore trimmed margins.\"}},{\"@type\":\"Question\",\"name\":\"Is Inventurus Knowledge Solutions trading above its IPO price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Yes, the share trades roughly 34% above its IPO price of Rs 1,329 based on the 10 September close. However, it is about 6% below its NSE listing price of Rs 1,900, so listing-day buyers are still slightly in the red.\"}},{\"@type\":\"Question\",\"name\":\"What is the 52-week high and low of Inventurus Knowledge Solutions?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The 52-week high is Rs 1,933 and the 52-week low is Rs 1,262 on NSE. The share traded near Rs 1,757 on 11 September 2026, down about 1.5% for the day.\"}},{\"@type\":\"Question\",\"name\":\"What is the Inventurus Knowledge Solutions share price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The consensus target from nine analysts is approximately Rs 1,965, implying about 12% upside from around Rs 1,757. Targets are estimates and can change after each quarterly result.\"}},{\"@type\":\"Question\",\"name\":\"Is this healthcare tech stock overvalued?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It trades at a PE of approximately 40 versus an industry PE of about 18, which is a clear premium for a healthcare tech stock. That premium reflects high returns on equity and strong profit growth, but it leaves little room for disappointment.\"}},{\"@type\":\"Question\",\"name\":\"What are the main risks for Inventurus Knowledge Solutions?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Key risks include higher debt from the TruBridge purchase, a lower-than-expected TruBridge revenue base, dependence on US clients and currency moves, and fee pressure from AI tools. A SEBI-registered advisor can help assess whether the stock suits your portfolio.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>One US-focused healthcare services and software company turned about Rs 1 lakh into roughly Rs 1.29 lakh in six months. Here is what drove the move and the risks investors should weigh.<\/p>\n","protected":false},"author":29,"featured_media":243187,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[845],"tags":[],"class_list":["post-243188","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-best-stocks"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["243187"],"rank_math_title":["Healthcare Tech Stock Up 29% in 6 Months: What Drove It"],"rank_math_description":["This healthcare tech stock rose approximately 29% in 6 months to Rs 1,784. See the FY26 profit jump, the US acquisition, Q1 FY27 numbers, analyst target and key risks."],"rank_math_focus_keyword":["healthcare tech stock"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/09\/healthcare-tech-stock-rises-29-percent-in-6-months.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/243188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=243188"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/243188\/revisions"}],"predecessor-version":[{"id":243189,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/243188\/revisions\/243189"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/243187"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=243188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=243188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=243188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}